The Grizzly, December 3, 1982

Graterford Prisoners Counseled • Phi Psi Sponsors Santa • Chem Society Rated Outstanding • Renowned Professor Dies • Steinbright Scholarships Offered • News Briefs: Sigma Pi Sigma Inducts New Members; Operation Native Talent; New Evening School Class; Winterfest II Schedules Events; Going for Baroque • Commuters Don\u27t Get No Respect! • Letters to the Editor • Is Tuition Increase Justified? • Recent Thefts and Attacks Prompt Security Questions • Cheating at Ursinus? • A Last Squeeze Before Departing • The Missionary: A Blessing • Roving Reporter: How Do You Feel About the New Security System in the Quad? • Challenge Yourself at Outward Bound • The Perfect Man • UC Faculty Not Burnt Out • Sports Profile: Mullahy and Bazow, Football Captains • Women\u27s Basketball Tops Aggies in Opener: Jankauskas Scoring and Rebounding Was Key • UC Making a Contribution to Olympic Efforthttps://digitalcommons.ursinus.edu/grizzlynews/1090/thumbnail.jp

The Grizzly, November 13, 1981

Suspicious Visitor Causes Alarm • Whistle Blowing: The Problem of Ethics in Business • Two Students Caught In Breaking and Entering • Pledging Discussion • Student Teachers Putting in Their Hours • Powlette Speaks on Values • USGA Notes • Students Attend Orchestra Concert in Philadelphia • Ursinus Represented at PCCA Choir Festival • Winterfest Brings Culture Shock to UC • Study Abroad Series: Gidget Goes to Rome • UC Attempts \u27World\u27s Largest Sandcastle\u27 • Davis Selected All-American • Dickinson vs Bears in ECAC Championship • Student Plays for Peru in Pan Am Games • Swimmers Enthusiastic About New Season • Fencing Foils F&M • Bears End Disappointing Season With Loss • Grapplers Anxious To Begin • U.C. Harriers MAC Champs... Againhttps://digitalcommons.ursinus.edu/grizzlynews/1067/thumbnail.jp

The Grizzly, September 18, 1981

Thomas P. Glassmoyer Elected Board President • APO Retains Highest GPA Last Spring • Chemistry, Economics, History and English Departments Receive New Faculty • Forum Programs Now \u27til Christmas • Editorial: Just Like the Good Old Days? • Message From the President: Play an Active Part • Evening in Photography Offered • Evening School Expands Computer Program • New Staff Appointments • Dr. Schultze Represents UC in Conference • UC Buying Up Main Street: New Off-Campus Housing • Anarchy in America: Let\u27s Kill All the Lawyers • Decatur Follows Shakespeare to Germany • Electric Factory Does it Again • IFC Getting it All Together • USGA Notes • Six New Faculty • Improving Relationships and Self-Image Workshop • Lacrosse Club Announces Fall Season • Gridders Kick Off \u2781 Season With Victory • Field Hockey Looking Good • Cross Country Team Off to Fast Starthttps://digitalcommons.ursinus.edu/grizzlynews/1060/thumbnail.jp

A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults

<div><h3>Background</h3><p>We conducted a phase I, randomized, double-blind, placebo-controlled trial to assess the safety and immunogenicity of escalating doses of two recombinant replication defective adenovirus serotype 35 (Ad35) vectors containing gag, reverse transcriptase, integrase and nef (Ad35-GRIN) and env (Ad35-ENV), both derived from HIV-1 subtype A isolates. The trial enrolled 56 healthy HIV-uninfected adults.</p> <h3>Methods</h3><p>Ad35-GRIN/ENV (Ad35-GRIN and Ad35-ENV mixed in the same vial in equal proportions) or Ad35-GRIN was administered intramuscularly at 0 and 6 months. Participants were randomized to receive either vaccine or placebo (10/4 per group, respectively) within one of four dosage groups: Ad35-GRIN/ENV 2×10⁹ (A), 2×10¹⁰ (B), 2×10¹¹ (C), or Ad35-GRIN 1×10¹⁰ (D) viral particles.</p> <h3>Results</h3><p>No vaccine-related serious adverse event was reported. Reactogenicity events reported were dose-dependent, mostly mild or moderate, some severe in Group C volunteers, all transient and resolving spontaneously. IFN-γ ELISPOT responses to any vaccine antigen were detected in 50, 56, 70 and 90% after the first vaccination, and in 75, 100, 88 and 86% of Groups A–D vaccine recipients after the second vaccination, respectively. The median spot forming cells (SFC) per 10⁶ PBMC to any antigen was 78–139 across Groups A–C and 158–174 in Group D, after each of the vaccinations with a maximum of 2991 SFC. Four to five HIV proteins were commonly recognized across all the groups and over multiple timepoints. CD4+ and CD8+ T-cell responses were polyfunctional. Env antibodies were detected in all Group A–C vaccinees and Gag antibodies in most vaccinees after the second immunization. Ad35 neutralizing titers remained low after the second vaccination.</p> <h3>Conclusion/Significance</h3><p>Ad35-GRIN/ENV reactogenicity was dose-related. HIV-specific cellular and humoral responses were seen in the majority of volunteers immunized with Ad35-GRIN/ENV or Ad35-GRIN and increased after the second vaccination. T-cell responses were broad and polyfunctional.</p> <h3>Trial Registration</h3><p>ClinicalTrials.gov <a href="http://clinicaltrials.gov/ct2/results?term=NCT00851383">NCT00851383</a></p> </div

Structural Modeling and DNA Binding Autoinhibition Analysis of Ergp55, a Critical Transcription Factor in Prostate Cancer

BACKGROUND: The Ergp55 protein belongs to Ets family of transcription factor. The Ets proteins are highly conserved in their DNA binding domain and involved in various development processes and regulation of cancer metabolism. To study the structure and DNA binding autoinhibition mechanism of Ergp55 protein, we have produced full length and smaller polypeptides of Ergp55 protein in E. coli and characterized using various biophysical techniques. RESULTS: The Ergp55 polypeptides contain large amount of α-helix and random coil structures as measured by circular dichorism spectroscopy. The full length Ergp55 forms a flexible and elongated molecule as revealed by molecular modeling, dynamics simulation and structural prediction algorithms. The binding analyses of Ergp55 polypeptides with target DNA sequences of E74 and cfos promoters indicate that longer fragments of Ergp55 (beyond the Ets domain) showed the evidence of auto-inhibition. This study also revealed the parts of Ergp55 protein that mediate auto-inhibition. SIGNIFICANCE: The current study will aid in designing the compounds that stabilize the inhibited form of Ergp55 and inhibit its binding to promoter DNA. It will contribute in the development of drugs targeting Ergp55 for the prostate cancer treatment

Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa

We conducted a double-blind, randomized, placebo-controlled Phase I study of a recombinant replication-defective adenovirus type 5 (rAd5) vector expressing HIV-1 Gag and Pol from subtype B and Env from subtypes A, B and C, given alone or as boost following a DNA plasmid vaccine expressing the same HIV-1 proteins plus Nef, in 114 healthy HIV-uninfected African adults.Volunteers were randomized to 4 groups receiving the rAd5 vaccine intramuscularly at dosage levels of 1×10(10) or 1×10(11) particle units (PU) either alone or as boost following 3 injections of the DNA vaccine given at 4 mg/dose intramuscularly by needle-free injection using Biojector® 2000. Safety and immunogenicity were evaluated for 12 months. Both vaccines were well-tolerated. Overall, 62% and 86% of vaccine recipients in the rAd5 alone and DNA prime - rAd5 boost groups, respectively, responded to the HIV-1 proteins by an interferon-gamma (IFN-γ) ELISPOT. The frequency of immune responses was independent of rAd5 dosage levels. The highest frequency of responses after rAd5 alone was detected at 6 weeks; after DNA prime - rAd5 boost, at 6 months (end of study). At baseline, neutralizing antibodies against Ad5 were present in 81% of volunteers; the distribution was similar across the 4 groups. Pre-existing immunity to Ad5 did not appear to have a significant impact on reactogenicity or immune response rates to HIV antigens by IFN-γ ELISPOT. Binding antibodies against Env were detected in up to 100% recipients of DNA prime - rAd5 boost. One volunteer acquired HIV infection after the study ended, two years after receipt of rAd5 alone.The HIV-1 rAd5 vaccine, either alone or as a boost following HIV-1 DNA vaccine, was well-tolerated and immunogenic in African adults. DNA priming increased the frequency and magnitude of cellular and humoral immune responses, but there was no effect of rAd5 dosage on immunogenicity endpoints.ClinicalTrials.gov NCT00124007

Overconfident Investors, Predictable Returns, and Excessive Trading

The last several decades have witnessed a shift away from a fully rational paradigm of financial markets toward one in which investor behavior is influenced by psychological biases. Two principal factors have contributed to this evolution: a body of evidence showing how psychological bias affects the behavior of economic actors; and an accumulation of evidence that is hard to reconcile with fully rational models of security market trading volumes and returns. In particular, asset markets exhibit trading volumes that are high, with individuals and asset managers trading aggressively, even when such trading results in high risk and low net returns. Moreover, asset prices display patterns of predictability that are difficult to reconcile with rational-expectations–based theories of price formation. In this paper, we discuss the role of overconfidence as an explanation for these patterns